UPDATE: Investment Firm Agitates for Change in Enzo Biochem's Board | GenomeWeb

This story has been updated to include comments from advisory firm Glass Lewis.

NEW YORK (GenomeWeb) – Investment firm Lone Star Value Management has issued an open letter to all Enzo Biochem shareholders, urging them to vote for two Lone Star nominees to Enzo's board of directors.

In the letter published Tuesday, Lone Star said it has "serious concerns" with Enzo's "poor performance and disregard for shareholder rights."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.